VHL and kidney cancer: Though, seven FDA-supported agents, targeting the VHL pathway, had been admitted for the therapy of patients with advanced kidney cancer, further genomic studies, such as whole genome sequencing, gene expression patterns, and so on, will still be needed to get a complete understanding of the genetic basic mechanism of kidney cancer and the kidney cancer gene pathways and, most importantly, to provide the foundation for the development of effective forms of therapy for patients with the disease [18].